439 related articles for article (PubMed ID: 23496764)
1. A requirement for wild-type Ras isoforms in mutant KRas-driven signalling and transformation.
Bentley C; Jurinka SS; Kljavin NM; Vartanian S; Ramani SR; Gonzalez LC; Yu K; Modrusan Z; Du P; Bourgon R; Neve RM; Stokoe D
Biochem J; 2013 Jun; 452(2):313-20. PubMed ID: 23496764
[TBL] [Abstract][Full Text] [Related]
2. Reduced HRAS G12V-Driven Tumorigenesis of Cell Lines Expressing KRAS C118S.
Huang L; Counter CM
PLoS One; 2015; 10(4):e0123918. PubMed ID: 25902334
[TBL] [Abstract][Full Text] [Related]
3. The mutational spectrum of HRAS, KRAS, NRAS and FGFR3 genes in bladder cancer.
Ouerhani S; Elgaaied AB
Cancer Biomark; 2011-2012; 10(6):259-66. PubMed ID: 22820081
[TBL] [Abstract][Full Text] [Related]
4. Absolute Quantification of Endogenous Ras Isoform Abundance.
Mageean CJ; Griffiths JR; Smith DL; Clague MJ; Prior IA
PLoS One; 2015; 10(11):e0142674. PubMed ID: 26560143
[TBL] [Abstract][Full Text] [Related]
5. Oncogenic RAS isoforms show a hierarchical requirement for the guanine nucleotide exchange factor SOS2 to mediate cell transformation.
Sheffels E; Sealover NE; Wang C; Kim DH; Vazirani IA; Lee E; M Terrell E; Morrison DK; Luo J; Kortum RL
Sci Signal; 2018 Sep; 11(546):. PubMed ID: 30181243
[TBL] [Abstract][Full Text] [Related]
6. Multiplexed screens identify RAS paralogues HRAS and NRAS as suppressors of KRAS-driven lung cancer growth.
Tang R; Shuldiner EG; Kelly M; Murray CW; Hebert JD; Andrejka L; Tsai MK; Hughes NW; Parker MI; Cai H; Li YC; Wahl GM; Dunbrack RL; Jackson PK; Petrov DA; Winslow MM
Nat Cell Biol; 2023 Jan; 25(1):159-169. PubMed ID: 36635501
[TBL] [Abstract][Full Text] [Related]
7. Interactions between wild-type and mutant Ras genes in lung and skin carcinogenesis.
To MD; Rosario RD; Westcott PM; Banta KL; Balmain A
Oncogene; 2013 Aug; 32(34):4028-33. PubMed ID: 22945650
[TBL] [Abstract][Full Text] [Related]
8. Comparison of liver oncogenic potential among human RAS isoforms.
Chung SI; Moon H; Ju HL; Kim DY; Cho KJ; Ribback S; Dombrowski F; Calvisi DF; Ro SW
Oncotarget; 2016 Feb; 7(6):7354-66. PubMed ID: 26799184
[TBL] [Abstract][Full Text] [Related]
9. Calmodulin and IQGAP1 activation of PI3Kα and Akt in KRAS, HRAS and NRAS-driven cancers.
Nussinov R; Zhang M; Tsai CJ; Jang H
Biochim Biophys Acta Mol Basis Dis; 2018 Jun; 1864(6 Pt B):2304-2314. PubMed ID: 29097261
[TBL] [Abstract][Full Text] [Related]
10. Non-Redundant and Overlapping Oncogenic Readouts of Non-Canonical and Novel Colorectal Cancer KRAS and NRAS Mutants.
Alcantara KMM; Malapit JRP; Yu RTD; Garrido JAMG; Rigor JPT; Angeles AKJ; Cutiongco-de la Paz EM; Garcia RL
Cells; 2019 Dec; 8(12):. PubMed ID: 31816869
[TBL] [Abstract][Full Text] [Related]
11. Anchorage-independent growth conditions reveal a differential SOS2 dependence for transformation and survival in
Sheffels E; Sealover NE; Theard PL; Kortum RL
Small GTPases; 2021 Jan; 12(1):67-78. PubMed ID: 31062644
[TBL] [Abstract][Full Text] [Related]
12. Differential oncogenic potential of activated RAS isoforms in melanocytes.
Whitwam T; Vanbrocklin MW; Russo ME; Haak PT; Bilgili D; Resau JH; Koo HM; Holmen SL
Oncogene; 2007 Jul; 26(31):4563-70. PubMed ID: 17297468
[TBL] [Abstract][Full Text] [Related]
13. The role of wild type RAS isoforms in cancer.
Zhou B; Der CJ; Cox AD
Semin Cell Dev Biol; 2016 Oct; 58():60-9. PubMed ID: 27422332
[TBL] [Abstract][Full Text] [Related]
14. A model for RAS mutation patterns in cancers: finding the sweet spot.
Li S; Balmain A; Counter CM
Nat Rev Cancer; 2018 Dec; 18(12):767-777. PubMed ID: 30420765
[TBL] [Abstract][Full Text] [Related]
15. Are all RAS mutations the same? Coexisting KRAS and NRAS mutations in a caecal adenocarcinoma and contiguous tubulovillous adenoma.
Vagaja NN; Parry J; McCallum D; Thomas MA; Bentel JM
J Clin Pathol; 2015 Aug; 68(8):657-60. PubMed ID: 25926041
[TBL] [Abstract][Full Text] [Related]
16. Further evidence for a somatic KRAS mutation in a pilocytic astrocytoma.
Janzarik WG; Kratz CP; Loges NT; Olbrich H; Klein C; Schäfer T; Scheurlen W; Roggendorf W; Weiller C; Niemeyer C; Korinthenberg R; Pfister S; Omran H
Neuropediatrics; 2007 Apr; 38(2):61-3. PubMed ID: 17712732
[TBL] [Abstract][Full Text] [Related]
17. BRAF, HRAS, KRAS, NRAS and CDKN2A genes analysis in cultured melanocytes used for vitiligo treatment.
Czajkowski R
Int J Dermatol; 2011 Feb; 50(2):180-3. PubMed ID: 21244382
[TBL] [Abstract][Full Text] [Related]
18. PIK3CA, HRAS and KRAS gene mutations in human penile cancer.
Andersson P; Kolaric A; Windahl T; Kirrander P; Söderkvist P; Karlsson MG
J Urol; 2008 May; 179(5):2030-4. PubMed ID: 18355852
[TBL] [Abstract][Full Text] [Related]
19. Rit, a non-lipid-modified Ras-related protein, transforms NIH3T3 cells without activating the ERK, JNK, p38 MAPK or PI3K/Akt pathways.
Rusyn EV; Reynolds ER; Shao H; Grana TM; Chan TO; Andres DA; Cox AD
Oncogene; 2000 Sep; 19(41):4685-94. PubMed ID: 11032018
[TBL] [Abstract][Full Text] [Related]
20. Evaluating The Role Of Nitric Oxide Synthase In Oncogenic Ras-Driven Tumorigenesis.
Counter C
Redox Biol; 2015 Aug; 5():417. PubMed ID: 28162280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
